Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Neuroinflammation
Published in: Journal of Neuroinflammation 1/2011

Open Access 01-12-2011 | Research

CCL2/MCP-1 modulation of microglial activation and proliferation

Authors: Ara E Hinojosa, Borja Garcia-Bueno, Juan C Leza, Jose LM Madrigal

Published in: Journal of Neuroinflammation | Issue 1/2011

Login to get access

Abstract

Background

Monocyte chemoattractant protein (CCL2/MCP-1) is a chemokine that attracts cells involved in the immune/inflammatory response. As microglia are one of the main cell types sustaining inflammation in brain, we proposed here to analyze the direct effects of MCP-1 on cultured primary microglia.

Methods

Primary microglia and neuronal cultures were obtained from neonatal and embryonic Wistar rats, respectively. Microglia were incubated with different concentrations of recombinant MCP-1 and LPS. Cell proliferation was quantified by measuring incorporation of bromodeoxyuridine (BrdU). Nitrite accumulation was measured using the Griess assay. The expression and synthesis of different proteins was measured by RT-PCR and ELISA. Cell death was quantified by measuring release of LDH into the culture medium.

Results

MCP-1 treatment (50 ng/ml, 24 h) did not induce morphological changes in microglial cultures. Protein and mRNA levels of different cytokines were measured, showing that MCP-1 was not able to induce proinflammatory cytokines (IL-1β, IL6, MIP-1α), either by itself or in combination with LPS. A similar lack of effect was observed when measuring inducible nitric oxide synthase (NOS2) expression or accumulation of nitrites in the culture media as a different indicator of microglial activation. MCP-1 was also unable to alter the expression of different trophic factors that were reduced by LPS treatment. In order to explore the possible release of other products by microglia and their potential neurotoxicity, neurons were co-cultured with microglia: no death of neurons could be detected when treated with MCP-1. However, the presence of MCP-1 induced proliferation of microglia, an effect opposite to that observed with LPS.

Conclusion

These data indicate that, while causing migration and proliferation of microglia, MCP-1 does not appear to directly activate an inflammatory response in this cell type, and therefore, other factors may be necessary to cause the changes that result in the neuronal damage commonly observed in situations where MCP-1 levels are elevated.
Appendix
Available only for authorised users
Literature
1.
Luster AD, Alon R, von Andrian UH: Immune cell migration in inflammation: present and future therapeutic targets. Nat Immunol. 2005, 6: 1182-1190. 10.1038/ni1275.CrossRefPubMed
2.
Rot A, von Andrian UH: Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu Rev Immunol. 2004, 22: 891-928. 10.1146/annurev.immunol.22.012703.104543.CrossRefPubMed
3.
4.
5.
Ransohoff RM, Perry VH: Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol. 2009, 27: 119-145. 10.1146/annurev.immunol.021908.132528.CrossRefPubMed
6.
Streit WJ, Xue QS: Life and death of microglia. J Neuroimmune Pharmacol. 2009, 4: 371-379. 10.1007/s11481-009-9163-5.CrossRefPubMed
7.
Wake H, Moorhouse AJ, Jinno S, Kohsaka S, Nabekura J: Resting microglia directly monitor the functional state of synapses in vivo and determine the fate of ischemic terminals. J Neurosci. 2009, 29: 3974-3980. 10.1523/JNEUROSCI.4363-08.2009.CrossRefPubMed
8.
Block ML, Hong JS: Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol. 2005, 76: 77-98. 10.1016/j.pneurobio.2005.06.004.CrossRefPubMed
9.
Ambrosini E, Aloisi F: Chemokines and glial cells: a complex network in the central nervous system. Neurochem Res. 2004, 29: 1017-1038.CrossRefPubMed
10.
Yadav A, Saini V, Arora S: MCP-1:chemoattractant with a role beyond immunity: a review. Clin Chim Acta. 2010, 411: 1570-1579. 10.1016/j.cca.2010.07.006.CrossRefPubMed
11.
Bruno V, Copani A, Besong G, Scoto G, Nicoletti F: Neuroprotective activity of chemokines against N-methyl-D-aspartate or beta-amyloid-induced toxicity in culture. Eur J Pharmacol. 2000, 399: 117-121. 10.1016/S0014-2999(00)00367-8.CrossRefPubMed
12.
El KJ, Toft M, Hickman SE, Means TK, Terada K, Geula C, et al: Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med. 2007, 13: 432-438. 10.1038/nm1555.CrossRef
13.
Eugenin EA, D'Aversa TG, Lopez L, Calderon TM, Berman JW: MCP-1 (CCL2) protects human neurons and astrocytes from NMDA or HIV-tat-induced apoptosis. J Neurochem. 2003, 85: 1299-1311. 10.1046/j.1471-4159.2003.01775.x.CrossRefPubMed
14.
Guyon A, Skrzydelski D, De G, Rovere C, Conductier G, Trocello JM, et al: Long term exposure to the chemokine CCL2 activates the nigrostriatal dopamine system: a novel mechanism for the control of dopamine release. Neuroscience. 2009, 162: 1072-1080. 10.1016/j.neuroscience.2009.05.048.CrossRefPubMed
15.
Kalehua AN, Nagel JE, Whelchel LM, Gides JJ, Pyle RS, Smith RJ, et al: Monocyte chemoattractant protein-1 and macrophage inflammatory protein-2 are involved in both excitotoxin-induced neurodegeneration and regeneration. Exp Cell Res. 2004, 297: 197-211. 10.1016/j.yexcr.2004.02.031.CrossRefPubMed
16.
Omata N, Yasutomi M, Yamada A, Iwasaki H, Mayumi M, Ohshima Y: Monocyte chemoattractant protein-1 selectively inhibits the acquisition of CD40 ligand-dependent IL-12-producing capacity of monocyte-derived dendritic cells and modulates Th1 immune response. J Immunol. 2002, 169: 4861-4866.CrossRefPubMed
17.
Melik-Parsadaniantz S, Rostene W: Chemokines and neuromodulation. J Neuroimmunol. 2008, 198: 62-68. 10.1016/j.jneuroim.2008.04.022.CrossRefPubMed
18.
Vairano M, Dello RC, Pozzoli G, Battaglia A, Scambia G, Tringali G, et al: Erythropoietin exerts anti-apoptotic effects on rat microglial cells in vitro. Eur J Neurosci. 2002, 16: 584-592. 10.1046/j.1460-9568.2002.02125.x.CrossRefPubMed
19.
Madrigal JL, Feinstein DL, Dello RC: Norepinephrine protects cortical neurons against microglial-induced cell death. J Neurosci Res. 2005, 81: 390-396. 10.1002/jnr.20481.CrossRefPubMed
20.
Kloss CU, Bohatschek M, Kreutzberg GW, Raivich G: Effect of lipopolysaccharide on the morphology and integrin immunoreactivity of ramified microglia in the mouse brain and in cell culture. Exp Neurol. 2001, 168: 32-46. 10.1006/exnr.2000.7575.CrossRefPubMed
21.
McQuibban GA, Gong JH, Wong JP, Wallace JL, Clark-Lewis I, Overall CM: Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood. 2002, 100: 1160-1167.PubMed
22.
Yao Y, Tsirka SE: The C terminus of mouse monocyte chemoattractant protein 1 (MCP1) mediates MCP1 dimerization while blocking its chemotactic potency. J Biol Chem. 2010, 285: 31509-31516. 10.1074/jbc.M110.124891.PubMedCentralCrossRefPubMed
23.
Belmadani A, Tran PB, Ren D, Miller RJ: Chemokines regulate the migration of neural progenitors to sites of neuroinflammation. J Neurosci. 2006, 26: 3182-3191. 10.1523/JNEUROSCI.0156-06.2006.PubMedCentralCrossRefPubMed
24.
Zhou Y, Tang H, Liu J, Dong J, Xiong H: Chemokine CCL2 modulation of neuronal excitability and synaptic transmission in rat hippocampal slices. J Neurochem. 2011, 116: 406-414. 10.1111/j.1471-4159.2010.07121.x.PubMedCentralCrossRefPubMed
25.
26.
Thompson WL, Karpus WJ, Van Eldik LJ: MCP-1-deficient mice show reduced neuroinflammatory responses and increased peripheral inflammatory responses to peripheral endotoxin insult. J Neuroinflammation. 2008, 5: 35-10.1186/1742-2094-5-35.PubMedCentralCrossRefPubMed
27.
Deshmane SL, Kremlev S, Amini S, Sawaya BE: Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res. 2009, 29: 313-326. 10.1089/jir.2008.0027.PubMedCentralCrossRefPubMed
28.
Rezaie P, Trillo-Pazos G, Everall IP, Male DK: Expression of beta-chemokines and chemokine receptors in human fetal astrocyte and microglial co-cultures: potential role of chemokines in the developing CNS. Glia. 2002, 37: 64-75. 10.1002/glia.1128.CrossRefPubMed
29.
Madrigal JL, Leza JC, Polak P, Kalinin S, Feinstein DL: Astrocyte-derived MCP-1 mediates neuroprotective effects of noradrenaline. J Neurosci. 2009, 29: 263-267. 10.1523/JNEUROSCI.4926-08.2009.CrossRefPubMed
30.
Yang G, Meng Y, Li W, Yong Y, Fan Z, Ding H, et al: Neuronal MCP-1 Mediates Microglia Recruitment and Neurodegeneration Induced by the Mild Impairment of Oxidative Metabolism. Brain Pathol. 2010
31.
Thacker MA, Clark AK, Bishop T, Grist J, Yip PK, Moon LD, et al: CCL2 is a key mediator of microglia activation in neuropathic pain states. Eur J Pain. 2009, 13: 263-272. 10.1016/j.ejpain.2008.04.017.CrossRefPubMed
32.
Muessel MJ, Klein RM, Wilson AM, Berman NE: Ablation of the chemokine monocyte chemoattractant protein-1 delays retrograde neuronal degeneration, attenuates microglial activation, and alters expression of cell death molecules. Brain Res Mol Brain Res. 2002, 103: 12-27.CrossRefPubMed
33.
Yokoyama A, Yang L, Itoh S, Mori K, Tanaka J: Microglia, a potential source of neurons, astrocytes, and oligodendrocytes. Glia. 2004, 45: 96-104. 10.1002/glia.10306.CrossRefPubMed
34.
Kauppinen TM, Swanson RA: Poly(ADP-ribose) polymerase-1 promotes microglial activation, proliferation, and matrix metalloproteinase-9-mediated neuron death. J Immunol. 2005, 174: 2288-2296.CrossRefPubMed
35.
Mander P, Brown GC: Activation of microglial NADPH oxidase is synergistic with glial iNOS expression in inducing neuronal death: a dual-key mechanism of inflammatory neurodegeneration. J Neuroinflammation. 2005, 2: 20-10.1186/1742-2094-2-20.PubMedCentralCrossRefPubMed
36.
Graeber MB, Streit WJ: Microglia: biology and pathology. Acta Neuropathol. 2010, 119: 89-105. 10.1007/s00401-009-0622-0.CrossRefPubMed
37.
Shimojo M, Nakajima K, Takei N, Hamanoue M, Kohsaka S: Production of basic fibroblast growth factor in cultured rat brain microglia. Neurosci Lett. 1991, 123: 229-231. 10.1016/0304-3940(91)90937-O.CrossRefPubMed
38.
Lalancette-Hebert M, Gowing G, Simard A, Weng YC, Kriz J: Selective ablation of proliferating microglial cells exacerbates ischemic injury in the brain. J Neurosci. 2007, 27: 2596-2605. 10.1523/JNEUROSCI.5360-06.2007.CrossRefPubMed
39.
Morrison RS, Sharma A, de VJ, Bradshaw RA: Basic fibroblast growth factor supports the survival of cerebral cortical neurons in primary culture. Proc Natl Acad Sci USA. 1986, 83: 7537-7541. 10.1073/pnas.83.19.7537.PubMedCentralCrossRefPubMed
40.
Walicke P, Cowan WM, Ueno N, Baird A, Guillemin R: Fibroblast growth factor promotes survival of dissociated hippocampal neurons and enhances neurite extension. Proc Natl Acad Sci USA. 1986, 83: 3012-3016. 10.1073/pnas.83.9.3012.PubMedCentralCrossRefPubMed
41.
Aberg ND, Brywe KG, Isgaard J: Aspects of growth hormone and insulin-like growth factor-I related to neuroprotection, regeneration, and functional plasticity in the adult brain. ScientificWorldJournal. 2006, 6: 53-80.CrossRefPubMed
42.
O'Donnell SL, Frederick TJ, Krady JK, Vannucci SJ, Wood TL: IGF-I and microglia/macrophage proliferation in the ischemic mouse brain. Glia. 2002, 39: 85-97. 10.1002/glia.10081.CrossRefPubMed
43.
Perez-Martin M, Cifuentes M, Grondona JM, Lopez-Avalos MD, Gomez-Pinedo U, Garcia-Verdugo JM, et al: IGF-I stimulates neurogenesis in the hypothalamus of adult rats. Eur J Neurosci. 2010, 31: 1533-1548.PubMed
44.
Chiu K, Yeung SC, So KF, Chang RC: Modulation of morphological changes of microglia and neuroprotection by monocyte chemoattractant protein-1 in experimental glaucoma. Cell Mol Immunol. 2010, 7: 61-68. 10.1038/cmi.2009.110.PubMedCentralCrossRefPubMed
45.
Zhang J, Shi XQ, Echeverry S, Mogil JS, De KY, Rivest S: Expression of CCR2 in both resident and bone marrow-derived microglia plays a critical role in neuropathic pain. J Neurosci. 2007, 27: 12396-12406. 10.1523/JNEUROSCI.3016-07.2007.CrossRefPubMed
46.
Kalinin S, Gavrilyuk V, Polak PE, Vasser R, Zhao J, Heneka MT, et al: Noradrenaline deficiency in brain increases beta-amyloid plaque burden in an animal model of Alzheimer's disease. Neurobiol Aging. 2007, 28: 1206-1214. 10.1016/j.neurobiolaging.2006.06.003.CrossRefPubMed
47.
Heneka MT, Ramanathan M, Jacobs AH, Dumitrescu-Ozimek L, Bilkei-Gorzo A, Debeir T, et al: Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J Neurosci. 2006, 26: 1343-1354. 10.1523/JNEUROSCI.4236-05.2006.CrossRefPubMed
48.
Madrigal JL, Dello RC, Gavrilyuk V, Feinstein DL: Effects of noradrenaline on neuronal NOS2 expression and viability. Antioxid Redox Signal. 2006, 8: 885-892. 10.1089/ars.2006.8.885.CrossRefPubMed
49.
Bondareff W, Mountjoy CQ, Roth M: Selective loss of neurones of origin of adrenergic projection to cerebral cortex (nucleus locus coeruleus) in senile dementia. Lancet. 1981, 1: 783-784.CrossRefPubMed
50.
Fornai F, di Poggio AB, Pellegrini A, Ruggieri S, Paparelli A: Noradrenaline in Parkinson's disease: from disease progression to current therapeutics. Curr Med Chem. 2007, 14: 2330-2334. 10.2174/092986707781745550.CrossRefPubMed
51.
Polak PE, Kalinin S, Feinstein DL: Locus coeruleus damage and noradrenaline reductions in multiple sclerosis and experimental autoimmune encephalomyelitis. Brain. 2011, 134: 665-677. 10.1093/brain/awq362.PubMedCentralCrossRefPubMed
Metadata
Title
CCL2/MCP-1 modulation of microglial activation and proliferation
Authors
Ara E Hinojosa
Borja Garcia-Bueno
Juan C Leza
Jose LM Madrigal
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Journal of Neuroinflammation / Issue 1/2011
Electronic ISSN: 1742-2094
DOI
https://doi.org/10.1186/1742-2094-8-77

Other articles of this Issue 1/2011

Journal of Neuroinflammation 1/2011 Go to the issue

Research

Participation of MCP-induced protein 1 in lipopolysaccharide preconditioning-induced ischemic stroke tolerance by regulating the expression of proinflammatory cytokines

Research

Activation of retinal microglia rather than microglial cell density correlates with retinal neovascularization in the mouse model of oxygen-induced retinopathy

Research

The formyl peptide receptor like-1 and scavenger receptor MARCO are involved in glial cell activation in bacterial meningitis

Research

Delayed inflammatory mRNA and protein expression after spinal cord injury

Research

Differential aquaporin 4 expression during edema build-up and resolution phases of brain inflammation

Research

Origin and consequences of brain Toll-like receptor 4 pathway stimulation in an experimental model of depression